Vibrio cholerae O139 multiple-drug resistance mediated by Yersinia pestis pIP1202-like conjugative plasmids.

Antimicrobial Agents and Chemotherapy
Jing-Cao PanZhe-Sheng He

Abstract

A conjugative plasmid, pMRV150, which mediated multiple-drug resistance (MDR) to at least six antibiotics, including ampicillin, streptomycin, gentamicin, tetracycline, chloramphenicol, and trimethoprim-sulfamethoxazole, was identified in a Vibrio cholerae O139 isolate from Hangzhou, eastern China, in 2004. According to partial pMRV150 DNA sequences covering 15 backbone regions, the plasmid is most similar to pIP1202, an IncA/C plasmid in an MDR Yersinia pestis isolate from a Madagascar bubonic plague patient, at an identity of 99.99% (22,180/22,183 nucleotides). pMRV150-like plasmids were found in only 7.69% (1/13) of the O139 isolates tested during the early period of the O139 epidemic in Hangzhou (1994, 1996, and 1997); then the frequency increased gradually from 60.00% (3/5) during 1998 and 1999 to 92.16% (47/51) during 2000 to 2006. Most (42/51) of the O139 isolates bearing pMRV150-like plasmids were resistant to five to six antibiotics, whereas the plasmid-negative isolates were resistant only to one to three antibiotics. In 12 plasmid-bearing O139 isolates tested, the pMRV150-like plasmids ranged from approximately 140 kb to 170 kb and remained at approximately 1 or 2 copies per cell. High (4.50 x 10(-2) and 3.08 x 10(-2...Continue Reading

References

Oct 1, 1976·Antimicrobial Agents and Chemotherapy·M M RahamanM R Islam
Apr 1, 1977·Antimicrobial Agents and Chemotherapy·R W HedgesF O'Grady
Nov 1, 1988·The American Journal of Tropical Medicine and Hygiene·M J FinchM M Levine
Jun 1, 1980·Annals of Emergency Medicine·S L Hoffman
Apr 1, 1995·FEMS Immunology and Medical Microbiology·T YamamotoY Takeda
Jun 1, 1994·Journal of Bacteriology·C LlanesY Michel-Briand
Oct 1, 1995·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·H KruseO Olsvik
Sep 4, 1997·The New England Journal of Medicine·M GalimandP Courvalin
Apr 11, 2000·Emerging Infectious Diseases·A BasuG B Nair
Oct 16, 2001·Antimicrobial Agents and Chemotherapy·B HochhutM K Waldor
Jan 23, 2003·Proceedings of the National Academy of Sciences of the United States of America·Shah M FaruqueG Balakrish Nair
Oct 2, 2003·Emerging Infectious Diseases·Shah M FaruqueDavid A Sack
Jun 25, 2004·Antimicrobial Agents and Chemotherapy·Masaaki IwanagaMasahiko Ehara
Dec 29, 2004·FEMS Microbiology Letters·Ashraf M AhmedTadashi Shimamoto
Oct 26, 2005·Transactions of the Royal Society of Tropical Medicine and Hygiene·B V S KrishnaM R Chandrasekhar
Sep 19, 2006·The Journal of Antimicrobial Chemotherapy·Daniela CeccarelliMauro Maria Colombo
Mar 22, 2007·PloS One·Timothy J WelchJacques Ravel

❮ Previous
Next ❯

Citations

Sep 22, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sergio BorgiaRoberto G Melano
Jul 30, 2011·Current Opinion in Infectious Diseases·Richelle C Charles, Edward T Ryan
Mar 25, 2009·Antimicrobial Agents and Chemotherapy·Nick J EvershedRuth M Hall
Jul 17, 2010·Antimicrobial Agents and Chemotherapy·Mark A Toleman, Timothy R Walsh
Nov 26, 2008·Antimicrobial Agents and Chemotherapy·Timothy J WelchDavid Wise
May 24, 2011·Applied and Environmental Microbiology·Murugan SubbiahDouglas R Call
Feb 22, 2012·Applied and Environmental Microbiology·Kevin S LangTimothy J Johnson
Jun 2, 2009·Journal of Bacteriology·W Florian FrickeJacques Ravel
Jul 28, 2009·Journal of Bacteriology·Grégory Léon, Paul H Roy
Oct 25, 2011·Journal of Bacteriology·José-Manuel Rodríguez-MartínezLaurent Poirel
Dec 31, 2009·PLoS Genetics·Rachel A F WozniakMatthew K Waldor
Aug 21, 2012·PloS One·Alejandro H BuschmannFelipe C Cabello
Oct 19, 2011·Future Microbiology·Mobashar Hussain Urf Turabe Fazil, Durg V Singh
May 29, 2013·Environmental Microbiology·Felipe C CabelloAlejandro H Buschmann
Jan 22, 2011·Journal of Medical Microbiology·Maya KitaokaStefan Pukatzki
Jul 7, 2011·FEMS Microbiology Reviews·Mark A Toleman, Timothy R Walsh
Jun 16, 2015·Frontiers in Microbiology·Marta Piotrowska, Magdalena Popowska
Jan 28, 2014·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Rachana BanerjeeSurajit Basak
Dec 24, 2014·International Journal of Antimicrobial Agents·Ruibai WangBiao Kan
Nov 3, 2016·Frontiers in Public Health·Daniela CeccarelliRita R Colwell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.